![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-to-market-generic-diabetes-drug/articleshow/102302377.cms
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-to-market-generic-diabetes-drug/articleshow/102302377.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-for-generic-diabetes-drug/articleshow/98003535.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-tentative-usfda-nod-for-generic-anti-diabetes-tablets/articleshow/75444093.cms
http://www.pharmatimes.com/news/xospata_leads_latest_chmp_recommendations_1302120
https://www.raps.org/news-and-articles/news-articles/2019/9/emas-chmp-recommends-three-new-medicines
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206020
https://pharmaphorum.com/news/az-hopes-diabetes-drug-could-be-as-effective-as-gastric-band/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-qtern-dapagliflozin-and-saxagliptin-tablets-1520055306.pdf
https://www.fiercepharma.com/pharma/busy-az-posts-q4-beats-as-execs-promise-light-at-end-tunnel
http://www.pharmatimes.com/news/az_books_3_percent_sales_drop_for_q3_1210956
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205994
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205994
http://www.fiercepharma.com/pharma/az-bms-slapped-14-lawsuits-over-onglyza-heart-failure-risks
http://www.pharmatimes.com/news/fda_rejects_cv_outcomes_claim_for_merck_diabetes_drugs_1191111
http://www.fiercepharma.com/marketing/merck-and-pfizer-prep-for-battle-sglt2-combo-diabetes-filings
http://www.pmlive.com/pharma_news/az_gets_us_approval_for_diabetes_combo_qtern_1187741
http://www.fiercepharma.com/pharma/az-bounces-back-diabetes-combo-win-but-can-it-keep-up-lilly-and-bi
http://www.pharmatimes.com/news/uk_sees_first_global_launch_of_az_diabetes_combo_qtern_1184989
https://www.pharmacompass.com/pdf/news/sun-pharmaceuticals-bortezomib-sun-bortezomib-receive-market-authorisation-in-eu-for-multiple-myeloma-1464602116.pdf
http://www.fiercepharma.com/pharma/az-s-lynparza-misses-mark-gastric-cancer-trial
https://www.pharmacompass.com/pdf/news/aurobindo-pharmas-generic-saxagliptin-tentatively-approved-in-us-as-an-anti-diabetic-drug-1454147188.pdf
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-rejects-compulsory-license-application-of-lee-pharma-against-astrazenecas-saxagliptin/articleshow/50652935.cms
http://twofourinsight.com/india-patent-office-rejects-lee-pharma-compulsory-license-application/
https://www.pharmacompass.com/pdf/news/amneal-pharmas-saxagliptin-tentatively-approved-in-us-as-an-orally-active-inhibitor-of-the-dpp4-enzyme-1453550508.pdf
https://www.pharmacompass.com/pdf/news/amneal-pharmas-saxagliptin-metformin-hcl-tentatively-approved-in-us-to-improve-glycemic-control-in-adults-with-type-2-diabetes-mellitus-1453550569.pdf
http://health.economictimes.indiatimes.com/news/pharma/british-drug-maker-astrazeneca-may-launch-innovative-drugs-in-india/50570752
http://www.business-standard.com/article/companies/astrazeneca-seeks-hearing-with-patent-controller-regarding-lee-pharma-s-cl-application-115121600915_1.html
http://www.fiercepharma.com/story/more-formulary-exclusions-are-their-way-smaller-pbms-get-action/2015-12-02
http://www.thehindubusinessline.com/companies/lee-pharma-to-appear-for-fresh-hearing-on-compulsory-licence/article7888775.ece
http://www.fiercepharma.com/story/fda-warning-jjs-invokana-adds-more-complexities-diabetes-drug-battles/2015-09-11?utm_medium=rss&utm_source=rss&utm_campaign=rss
http://in.reuters.com/article/2015/08/28/us-diabetes-drugs-warning-idINKCN0QX25E20150828
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-rejects-lee-pharmas-compulsory-licence-plea/articleshow/48521191.cms
http://www.fiercepharma.com/story/fdas-sglt2-warning-bad-news-az-jj-and-lilly-could-be-boon-merck/2015-05-18
http://blogs.wsj.com/pharmalot/2015/04/28/merck-gains-edge-on-rivals-with-results-about-its-diabetes-drug/
http://www.fiercepharma.com/story/onglyzas-label-should-flag-heart-failure-risks-fda-panel-says/2015-04-14
http://www.pmlive.com/pharma_news/astrazeneca_bullish_on_diabetes_franchise_fortunes_676415